HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner by Rabachini, Tatiana et al.
RESEARCH ARTICLE Open Access
HPV-16 E7 expression up-regulates
phospholipase D activity and promotes
rapamycin resistance in a pRB-dependent
manner
Tatiana Rabachini1* , Enrique Boccardo1,3, Rubiana Andrade3, Katia Regina Perez2,4, Suely Nonogaki5,
Iolanda Midea Cuccovia2 and Luisa Lina Villa1,6
Abstract
Background: Human Papillomavirus (HPV) infection is the main risk factor for the development and progression of
cervical cancer. HPV-16 E6 and E7 expression is essential for induction and maintenance of the transformed phenotype.
These oncoproteins interfere with the function of several intracellular proteins, including those controlling the PI3K/
AKT/mTOR pathway in which Phospolipase D (PLD) and Phosphatidic acid (PA) play a critical role.
Methods: PLD activity was measured in primary human keratinocytes transduced with retroviruses expressing HPV-16 E6,
E7 or E7 mutants. The cytostatic effect of rapamycin, a well-known mTOR inhibitor with potential clinical applications, was
evaluated in monolayer and organotypic cultures.
Results: HPV-16 E7 expression in primary human keratinocytes leads to an increase in PLD expression and
activity. Moreover, this activation is dependent on the ability of HPV-16 E7 to induce retinoblastoma protein
(pRb) degradation. We also show that cells expressing HPV-16 E7 or silenced for pRb acquire resistance to the
antiproliferative effect of rapamycin.
Conclusion: This is the first indication that HPV oncoproteins can affect PLD activity. Since PA can interfere
with the ability of rapamycin to bind mTOR, the use of combined strategies to target mTOR and PLD activity
might be considered to treat HPV-related malignancies.
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Background
Human papillomavirus (HPV) is the most prevalent sexu-
ally transmitted infection and a necessary cause of cervical
cancer, the third most common cancer in women world-
wide [1]. More than 99% of cervical cancers contain DNA
of HPV high-risk types [2]. In addition, HPV DNA is also
found in a significant percentage of other anogenital
lesions as well as oral and oropharyngeal tumors [3–5].
HPV-16 is the most prevalent type and it is found in
almost 50% of all cervical cancer cases [6]. The two major
HPV oncoproteins, E6 and E7, are consistently expressed
in all HPV positive cancers. The expression of these pro-
teins in primary human keratinocytes effectively induces
their immortalization [7]. Furthermore, when grown
under conditions that allow stratification and the forma-
tion of skin-like structures, cells immortalized with E6
and E7 from high-risk HPV types display morphological
hallmarks of high-grade squamous intra-epithelial lesions,
well-established precursors of cervical cancer [8]. The best
characterized activity of HPV-16 E6 and E7 is their ability
to bind to and induce the proteasome-mediated deg-
radation of tumor suppressors p53 and pRb, respect-
ively [9, 10]. Besides, both HPV-16 E6 and E7 are able
to bind to and alter the biological function of several
other cellular proteins [11]. Among them are many
members of the phosphatidylinositol (PI)-3-kinase
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(PI3K)/Akt/mammalian target of rapamycin (mTOR)
signaling pathway [12]. The PI3K/Akt/mTOR signal-
ing axis plays a very important role in HPV-induced
carcinogenesis by acting through multiple cellular and
molecular events [13]. Although the regulation of mTOR
through PI3K/AKT has been extensively described, an-
other mechanism contributing to activation of mTOR has
been proposed. Phosphatidic acid (PA), a product of
phospholipase D, is required for mTORC1 activation by
mitogens as well as amino acid signals [14–16]. More
recently, PA was identified as a major product capable of
displacing DEPTOR, a mTOR binding protein that nor-
mally functions to inhibit both mTORC1 and mTORC2
pathways [17]. PA species with unsaturated fatty acids
chains, such as those produced by PLD, bind with high
affinity to the FRB domain of mTOR in a manner that is
competitive with its inhibitor rapamycin. As a conse-
quence, elevated PLD activity has been associated to rapa-
mycin resistance [18, 19]. In addition, phospholipase D
enzymes play a fundamental role in cells: they maintain the
integrity of cellular membranes and they participate in cell
signaling including cytoskeletal dynamics, cell migration,
intracellular protein trafficking, and cell proliferation. Con-
sistent with this data, increased PLD activity has been re-
ported in a large number of human cancers, including
breast, colon, gastric, and kidney [20].
Our results show that upon HPV-16 E7 expression,
primary human foreskin keratinocytes upregulate PLD
protein levels and activity. Such effect is dependent on
the integrity of the E7 LxCxE binding motif and,
ultimately to the ability of HPV-16 E7 to induce pRb
degradation and promote immortalization. We also
show that organotypic cultures of keratinocytes ex-
pressing HPV-16 E7 become resistant to the antipro-
liferative effect of rapamycin.
Methods
Cell culture
Low passage-pooled neonatal foreskin keratinocytes or
Primary Human Keratinocytes (cat no. 192906) (Lonza
Walkersville, Inc., Walkersville, MD) were maintained in
K-SFM media supplemented with 5 μg/L EGF and
50 mg/L bovine pituitary extract (BPE) (Invitrogen,
Carlsbad, CA, USA).
Recombinant retroviruses and retroviral-mediated gene
transfer
Retroviral vectors pLXSN-neo, pLXSN-E6, −E7, −E6E7,
E7E26G and -E7CVQ68-70AAA were kindly provided
by Dr. Denise Galloway (Fred Hutchinson Cancer
Center, Seattle, USA). Recombinant retroviruses were
produced from the amphotropic packaging cell line GP
+ envAm12 as described earlier [21]. Early passage PHKs
were infected with different retroviruses at the same
multiplicity of infection (MOI).
pRb downregulation
Specific shRNAs clones for pRB silencing were selected
from the MISSION® shRNA Human Gene Family Set-
Tumor Suppressors (SH0531, Sigma-Aldrich, St. Louis,
MO, USA) and transfected in HEK-293 T cells (ATCC®
cat. no. 3216) together with MISSION® Lentiviral Pack-
aging Mix (Sigma-Aldrich, St. Louis, MO, USA) using
FuGENE® HD Transfection Reagent (Promega, Madison,
WI, USA) according to the manufacturer’s instructions.
Supernatants containing lentivirus were collected after
48 and 72 h after transfection. Lentiviral particles titer
was determined using an HIV-1 p24 antigen enzyme-
linked immunosorbent assay (ELISA) kit (ZeptoMetrix
Corporation, Buffalo, NY, USA). Sub-confluent cultures
of primary human keratinocytes were infected with lenti-
viral particles (MOI 5) expressing specific shRNA. After
2 days cells were selected with 2.5 μg/ml of puromycin
(Sigma-Aldrich, St. Louis, MO, USA) until complete
death of uninfected cells was observed.
Organotypic raft cultures
Organotypic raft cultures of PHK were prepared as
described elsewhere [22]. Raft cultures were allowed to
differentiate for 9 days and rapamycin (Calbiochem, San
Diego, CA, USA) was added to a final concentration of
100 ng/ml at day 6. Bromodeoxyuridine (BrdU) (Sigma-
Aldrich, St Louis, MO, USA) was added to a final con-
centration of 50 μg/ml for the last 12 h. The rafts were
then harvested, fixed in formalin and paraffin embedded.
Immunohistochemistry
Raft sections were deparaffinized and dehydrated in xylene
and alcohol sequential baths. The endogenous peroxidase
activity was quenched with 3% H2O2 after antigen retrieval
in boiling citrate buffer. Primary antibodies against BrdU
(1:400; Zymed, San Francisco, CA, USA), p53 DO-7 (1:400;
DakoCytomation, Glostrup, Denmark) and pRb (1:500;
Novocastra, Newcastle-upon-Tyne, UK) were incubated for
18 h in 1% bovine serum albumin-phosphate buffered so-
lution. After incubation with secondary antibody, anti-
gens were detected with streptavidin-biotin-peroxidase
complex (StreptABComplex/HRP Duet Mouse/Rabbit
DakoCytomation, Dako). Chromogenic detection of
peroxidase was performed with diaminobenzidine (DAB)
substrate (Sigma-Aldrich, St Louis, MO, USA). The per-
centage of BrdU-positive/total nuclei was determined by
direct counting cell nuclei. At least 3000 nuclei were
counted per experiment.
Rabachini et al. BMC Cancer  (2018) 18:485 Page 2 of 8
Cell proliferation assays
For Alamar blue based proliferation analysis cells silenced
with lentiviral particles (MOI 5) expressing the shRNA
described above and appropriate controls were seeded in
octuplicate in 96 wells plates (2000 cells/well). After 72 h
10 μL of Alamar blue (Life Technologies, Carlsbad, CA)
were added per well and cells were incubated at 37 °C for
4 to 7 h. After this period, Alamar Blue reduction was
monitored in at 570 e 600 nm in an Epoch Microplate
Spectrophotometer (Bio-Tek, Winooski, VT, USA).
For growth curves, cells were seeded in low density in
six-well plates and treated with rapamycin (100 ng/ml)
in the next day. Cell proliferation was assessed by cell
counting in the following 7 days.
Western-blot
Total protein extracts were obtained from monolayer
cultures of infected PHKs using lysis buffer (50 mM
Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% Sodium deox-
ycholate, 0.1% SDS) supplemented with complete mini
proteases inhibitors cocktail (Roche Diagnostics GmbH,
Mannheim, Germany). Whole cell lysates (60 μg) were
subjected to SDS-PAGE and transferred to PVDF
membranes (GE Healthcare, Buckinghamshire, UK).
Membranes were blocked with 5% non-fat dry milk and
incubated with PLD antibody (1:300; Upstate Biotech-
nology, Lake Placid, NY, USA), pRB antibody (1:500;
Novocastra NCL-RB-358; Leica Biosystems, Newcastle-
upon-Tyne, UK), actin antibody (1:1000; Sigma-Aldrich,
St. Louis, MO, USA), anti-HPV-16 E6 antibody (1:500)
and anti-HPV-16 E7 antibody (1:500) from Arbor Vita
Corporation (Fremont, CA, USA). The immunoreactive
bands were visualized by chemiluminescence using ECL
reagents (GE Healthcare, Buckinghamshire, UK).
Measurement of phospholipase D activity
To measure PLD activity, PHK infected with different
recombinant retrovirus were plated in 100 mm culture
dishes and allowed to reach about 80% confluence.
Cells were then pre-labeled with [3H] myristic acid
(Perkin-Elmer, Waltham, MA, USA) (6 μCi, 30 Ci/
mmol) in 4 ml of culture medium for 5 h. PLD activity
was determined by measuring the formation of [3H]
phosphatidylbutanol (PtBt), the product of PLD-
mediated trans-phosphatidylation, in the presence of
0.8% 1-Butanol (Sigma-Aldrich, St. Louis, MO, USA).
Lipid extraction and characterization were performed
by thin layer chromatography (TLC). Briefly, lipid ex-
tracts were counted in a scintillation counter to
normalize all samples. Approximately 500.000 CPM of
each sample were spotted onto TLC plates (silica gel
60A, Fisher Scientific, Fair Lawn, NJ, USA). TLC were
developed with the upper organic phase of a mixture
containing ethyl acetate:iso-octane:glacial acetic acid:
H2O (1.1:0.5:0.2:1, vol/vol) and allowed to dry before
being sprayed with En3hancer Spray (Perkin Elmer,
IL, USA). Phosphatidilbutanol was detected by auto-
radiography with Kodak BioMax MR Film (Kodak,
Rochester, NY, USA).
PLD activity in control and HPV gene-expressing
primary human keratinocytes after pRb downregula-
tion was determined using the Phospholipase D Assay
Kit (#700590, Cayman Chemicals, Ann Arbor, MI,
USA) according to the manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed by student’s unpaired
t-test using Graphpad Prism Software (Graphpad Soft-
ware, La Jolla, CA). All the experiments were performed
at least three times. p-values were considered two-tailed
and significance was defined as p < 0.05.”
Results
HPV-16 E7 expression increases PLD protein expression
and activity
PLD1 and PLD2 catalyze the hydrolysis of phosphatidyl-
choline (PC) to phosphatidic acid (PA) and choline [23].
Due to their vital role in cell signaling and proliferation
we sought to investigate if HPV-16 E7 expression could
promote any alteration in PLD expression and activity.
Our results show that primary human keratinocytes
(PHK), expressing HPV-16 E6 and E7 or E7 alone, show
an increase in both PLD1 and PLD2 isoforms when com-
pared with keratinocytes transduced only with the empty
vector (Fig. 1a). This fact was paralleled by an increase in
PLD activity (Fig. 1b). E6 expression alone did not pro-
mote any alterations in PLD activation (Additional file 1:
Figure S1). Interestingly, we observed that E7 ability to in-
duce PLD expression and activation is dependent on the
integrity of its LxCxE motif, as the E7E26G mutant failed to
induce PLD expression or increase its activity (Fig. 1a and
b). An intact LxCxE motif enables E7 protein to bind pRb
protein leading to the release of E2F transcriptional factor
and progression into S phase [24, 25]. On the other hand,
the E7 mutant (E7CVQ68-70AAA), that keeps the ability to
destabilize pRb family members [26], was able to
upregulate PLD like the WT E7 protein. Altogether these
data indicates that HPV-16 E7 promotes an upregulation
in PLD expression and activity and this effect is dependent
on the integrity of its LxCxE motif.
HPV-16 E7 induces PLD activation in a pRb dependent-
manner
We investigated if pRb inactivation, induced by HPV-16
E7, could be linked to PLD increased activation. To
address this question, foreskin primary human keratino-
cytes (PHK) were transduced with two different shRNAs
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targeting pRb. Retinoblastoma protein was strongly
downregulated in both cell lines when compared to PHK
transducing scrambled shRNA (Fig. 2a). Moreover, PLD
activity was strongly upregulated in cells with pRb de-
pleted (Fig. 2b). This result indicates that PLD activation,
induced by E7, is linked to its ability to induce pRb
degradation.
HPV-16 E7 expression confers resistance to the
antiproliferative effect of rapamycin
Elevated PLD activity has been previously linked to rapa-
mycin resistance [18]. Rapamycin is a highly specific in-
hibitor of mTOR and has been widely used to block cell
proliferation [27]. Considering this, we sought to study
the effect of rapamycin in the proliferation of human
keratinocytes expressing HPV-16 main oncogenes in
organotypic raft cultures of human keratinocytes. These
cultures exhibit highly reduced p53 and pRb expression
levels as an indication of the presence of functional E6 and
E7 (Additional file 2: Figure S2a). HPV-16 E6 and E7 ex-
pression was also confirmed by Western-blot (Additional
file 2: Figure S2b). In keratinocytes transduced with empty
vector, from now on referred as control cultures, DNA
synthesis was observed only in cells from the basal and
parabasal layers of the epithelium (Fig. 3a). After being
treated with rapamycin, control cultures showed 50% less
BrdU incorporation than the untreated tissue (Fig. 3b). On
the other hand, organotypic cultures of keratinocytes
expressing E6E7 were significantly resistant to the antipro-
liferative effect of rapamycin (Fig. 3a and b). In organo-
typic cultures expressing only HPV-16 E6, BrdU
incorporation rate decreased by 40% after rapamycin
treatment (Fig. 3a and b). Surprisingly, when PHK
were transduced only with HPV-16 E7 alone, rapamycin
treatment promoted an increase in BrdU incorporation.
Growth curve of monolayer cultures of keratinocytes
treated with 100 ng/ml rapamycin for 7 days also indicate
that PHK transduced with HPV-16 E7 alone proliferate
much faster than PHK transduced with the empty vector
(Fig. 3c). Interestingly, we also found that rapamycin treat-
ment increased rather than decreased PLD activity in
PHK expressing HPV-16 E7 (Fig. 3d). Our results show
that HPV-16 E7 expression in primary human keratino-
cytes not only confers resistance to the antiproliferative
Fig. 1 HPV-16 E7 expression increases PLD expression and activity. a
PLD expression levels were analyzed by Western-blot in PHK transduced
with empty vector, HPV-16 E6E7, wild-type E7 or E7 mutants E7E26G and
E7CVQ68-70AAA. b PLD activity was determined by trans-phosphatidylation
reaction in the presence of 1-butanol. Generation of phosphatidylbutanol
(PtBt) indicates increased PLD activity. PLD activity was normalized to that
in pLXSN transduced cells, which was given an arbitrary value of 1
Fig. 2 pRb downregulation leads to PLD activation in PHK. a Expression
of pRb in PHK was silenced using lentiviral particles codifying specific
shRNAs. Silencing efficiency was determined by western blot in 30
micrograms of total protein extracts. b The effect of pRb silencing on
PLD activity was determined using Phospholipase D kit according to
manufacture instructions. Error bars represent the standard deviation for
three independent experiments. (*) p< 0.05
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effect of rapamycin, but also promotes proliferation in
organotypic cultures expressing only this oncoprotein.
We also investigated if the integrity of the LxCxE E7
motif could affect rapamycin resistance. Our results
show that E7E26G expressing cultures were as sensitive to
rapamycin as control samples (Fig. 4a and b). On the
other hand, DNA synthesis was not affected by rapamycin
in cultures expressing the E7CVQ68-70AAA mutant
(Fig. 4a and b). We also observed that PHK expressing
shRNA against pRb are much more resistant to rapa-
mycin treatment than those transduced with scrambled
shRNA (Fig. 4c and d). This result indicates that rapa-
mycin resistance observed in these cultures is associ-
ated to the ability of E7 to induce pRb degradation.
Discussion
A growing body of evidences gathered during the past few
years point toward the role of PA in mTOR activation [15].
More recently, PA was identified as a major product cap-
able of displacing DEPTOR, a mTOR binding protein that
normally functions to inhibit both mTORC1 and mTORC2
pathways [17]. The major cellular mechanism for generat-
ing PA is through the hydrolysis of phosphatidylcholine by
PLD [20]. Here we show that HPV-16 E7, one of the major
HPV-16 oncoproteins, is able to induce both PLD expres-
sion and activity. Interestingly, PLD has been considered a
critical regulator of cell proliferation and abnormalities in
its activity have been observed in many human cancers
[23]. Additionally, PLD activity is elevated in cells trans-
formed by a variety of oncogenes including v-Src, v-Ras, v-
Fps and v-Raf [23]. We also demonstrate that PLD activa-
tion induced by E7 is dependent on the integrity of the
LxCxE motif. This particular region of HPV-16 E7 is
known to promote AKT activation in primary human kera-
tinocytes grown in organotypic cultures [28]. The LxCxE
motif of high-risk HPVs is also responsible for binding pRb
leading to E2F release. For this reason it was previously
linked to the ability of HPV-16 E7 to induce cellular trans-
formation [25, 26]. Considering this, we sought to investi-
gate if pRb inactivation could promote PLD activation. Our
results show that PHK depleted of pRb present an increase
in PLD expression and activity. Interestingly, E2F putative
Fig. 3 HPV-16 E7 expression confers resistance to the antiproliferative effect of rapamycin. a DNA synthesis in organotypic cultures of keratinocytes was
detected by BrdU incorporation followed by immunohistochemistry. Arrows indicate BrdU-positive nuclei. b The percentage of BrdU-positive/total nuclei
was determined by direct nuclei counting. The bars correspond to values obtained in at least three independent different experiments. (*)
p < 0.05. c Growth curve of monolayer cultures of keratinocytes treated with 100 ng/ml rapamycin for 7 days. Results are representative of
three independent experiments performed in triplicates. (*) p < 0.05; (**) p < 0.001. d Rapamycin treatment is associated with increased
PLD activity in cultures of PHK expressing HPV16 E7. PLD activity was determined as described in Fig. 2b. Scale bars, 20 μm
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binding sites were identified in PLD1 and PLD2 promoters
using the TRANSFAC database [29] and resistance to
mTOR inhibitors could be found in cells with defective
regulation of the retinoblastoma protein checkpoint [30]. In
line with this observation and the fact that PLD overexpres-
sion also confers resistance to the mTOR inhibitor rapamy-
cin, we investigated if cells expressing HPV-16 E7 could
also display rapamycin resistance. Our results indicate that
HPV-16 E7 is also capable to confer resistance to the anti-
proliferative effect of rapamycin. Supporting our previous
observation, this resistance was also associated to the integ-
rity of the LxCxE motif. This result is not without prece-
dent once E7 is also capable of inducing resistance to other
cytostatic agents such as TGF-β and TNF in an LxCxE
motif dependent-manner [31–33].
One limitation of our study is related to the fact that
exogenous PLD expression is associated to human kera-
tinocyte differentiation [21] which precludes the possi-
bility to test directly the effect of PLD overexpression in
rapamycin resistance in normal PHK. Nonetheless, our
results highlight the importance of HPV-16 E7 in
bypassing negative growth regulatory signals [34].
Intriguingly, we found that cultures of keratinocytes
expressing only HPV-16 E7 presented an increase in
proliferation and an increase in PLD activity after rapa-
mycin treatment. Although this effect was not seen in
cells expressing HPV-16 E6 concomitantly, this observa-
tion could help us to understand why HPV-associated
tumor xenografts generated in immuno-compromised
mice grow slower when rapamycin is administered daily
to the animals, but fail to lead to any long-term cure
Fig. 4 E7-mediated rapamycin resistance requires an intact LxCxE motif. a DNA synthesis in organotypic culture of keratinocytes expressing HPV-16 E7
mutants was detected by BrdU staining. Arrows indicate positive nuclei. b The percentage of BrdU-positive/total nuclei was determined by direct nuclei
counting. The bars correspond to values obtained in at least three independent experiments. (*) p < 0.05. c Growth curve of monolayer
cultures of keratinocytes treated with 100 ng/ml rapamycin for 7 days. Results are representative of three independent experiments
performed in triplicates. (*) p < 0.05; (**) p < 0.001. d Alamar Blue cell proliferation assay was used to evaluate the effect of rapamycin
on the proliferation of PHK silenced for pRb expression HPV16 E7 transduced PHKs. Gene silencing was performed as described in
Fig. 2. Experiments were carried out in triplicate for each time point. Scale bars, 20 μm
Fig. 5 A proposed model for HPV-16 E7 induced resistance to
rapamycin and PLD activation. In HPV-16 E7 expressing cells,
high intracellular PA levels, generated by increased PLD activity,
competes with rapamycin for mTOR binding leading to an increase in
cell proliferation
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[35]. Even with the treatment prolonging survival and
delaying cell proliferation, tumors cells could still grow
ultimately affecting survival [35]. For this reason, several
studies are suggesting the use of rapamycin in combin-
ation with other therapeutic drugs [36]. In fact, rapamy-
cin and rapamycin derivatives are being proposed as a
concurrent agent to standard-of-care cisplatin/radiation
therapy to attenuate tumor lactate production and in-
duce regression of (HPV)-related head and neck squa-
mous cell carcinomas (HNSCC) [36]. A proposed model
describing our findings is presented in Fig. 5.
Conclusions
Our work present evidences that HPV-16 E7 up-regulates
PLD activity. It also shows that the increase in PLD activa-
tion is related to the ability of E7 to induce pRb degrad-
ation. Moreover, we show that cells depleted of pRb
expression exhibit higher PLD activity. Supporting our
findings we present data indicating that both HPV-16 E7
expression and pRb depletion lead to resistance to the
antiproliferative effect of rapamycin. Considering the fact
that rapamycin and rapamycin analogs are being com-
bined with other chemotherapeutic drugs, it is possible
that rapamycin may be associated with PLD inhibitors to
circumvent rapamycin resistance exhibited by many types
of human cancers, including those related to HPV.
Further studies are warranted.
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